EC ever use among women of reproductive age: 0.9% (DHS 2005)
EC knowledge among women of reproductive age: 26.8% (DHS 2010)
Contraceptive Use: 26.1% (DHS 2005, ever use of any modern method among women of reproductive age)
Registered LNG-EC products:
- Escapelle* - Available directly from pharmacist without prescription (i.e. BTC)
- Postinor* - Available directly from pharmacist without prescription (i.e. BTC)
Registered UPA-EC products:
- Dvella* - Available only with prescription
Registered Mifepristone-EC Products:
- Gynepriston* - Available only with prescription
Products marked with * have been approved by a stringent regulatory authority, such as the WHO Prequalification Programme, the US Food and Drug Administration, the European Medicines Agency, or other.
Where at least one type of ECP is available: Private clinics, Pharmacies, IPPF-affiliated system
Age restrictions for accessing ECPs: No data available
Legal/regulatory documents in which EC is included: Essential Medicines List
Other relevant information: A product containing ulipristal acetate has been registered but is not yet on the market.
EC distributed via IPPF outlets (<500 in 2012).
In Armenia, the lowest cadre of health workers allowed to sell/dispense ECPs in the private sector is doctors, as of 2013. (USAID/DELIVER, Contraceptive Security Indicators, 2013)
In 2013, EC was not procured by the government (JSI/Deliver data).